Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses

INTRODUCTION: The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2 diabetes (T2D) in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) programme. The current post-hoc exploratory subgroup analyses...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Ther
Main Authors: Pratley, Richard E., Crowley, Matthew J., Gislum, Mette, Hertz, Christin L., Jensen, Thomas B., Khunti, Kamlesh, Mosenzon, Ofri, Buse, John B.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7994454/
https://ncbi.nlm.nih.gov/pubmed/33660198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00994-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados